arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

HUTCHMED (China) Ltd

HCM
$11.82 ▲ +0.28 (+2.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Bullish
auto_awesome

Analytical Summary

HUTCHMED (China) Ltd shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $10.1B
Dividend Yield
Revenue Growth -13.0%
Op. Margin -7.1%
ROIC -2.3%
FCF / Share $-0.09
Trailing P/E 22.3x
Price / Book 8.2x
FCF Yield
Debt / Equity 0.10
info Valuation on last close. End-of-day price, Aug 6, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$548.51M
↓ -13.0%
Net Income Profit after all expenses
$456.91M
↑ +1111.0%
Operating Margin Operating profit as % of sales
-7.1%
↓ -2.9% 18th
FCF / Share Free cash flow per share
$-0.09
↓ -350.4%
Long-Term Debt Long-term obligations
$93.16M
↑ +12.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
42
Returns
95
Financial Health
54
Cash Quality
17

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 13 quarters